- Global Pharma News & Resources

The Kinetix Group Partners with Rimidi to Launch a Clinical Care Partnership for the Management of Nonalcoholic Steatohepatitis (NASH)

NEW YORK, Aug. 30, 2018 /PRNewswire/ -- The Kinetix Group in partnership with Rimidi, an Atlanta-based health care technology firm, announced a partnership focused on improving Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH) care delivery leveraging NASHNET, a global centers of excellence network.

The global NASH market is projected to reach $25 Billion by 2025, with NASH being the leading cause of liver transplantation in the US in the next X-Y years1. Approximately 30% of the US population has NAFLD, the most common form of liver disease in the world. NASH, the more aggressive form of NAFLD, affects 10-12% of the population and has the propensity to progress to cirrhosis and hepatocellular cancer2. In addition, 60% to 80% of patients with type 2 diabetes have NAFLD and as many as 20% have NASH.

Many individuals with NAFLD remain undiagnosed and may even progress to NASH before a clinical diagnosis is confirmed. Lack of awareness in the medical community regarding recommended screening, interventions and treatment options for patients with NASH and NAFLD puts patients' lives at risk and drives unnecessary cost in the healthcare system.

To address this issue, The Kinetix Group and Rimidi have partnered with NASHNET to optimize a progressive NAFLD care delivery model, addressing major treatment gaps including early patient identification, appropriate referrals, intervention methodologies, and care coordination. By utilizing Rimidi's chronic disease management platform, the model is operationalized through electronic medical record (EMR) workflows in a scalable manner. The consistent execution of clinical actions based on the latest evidence-based guidelines will both improve patient outcomes and reduce costs.

"The Kinetix Group, together with NASHNET, have played a significant role in informing a best practice delivery model for NASH," said Lucienne Marie Ide, MD, PhD, Founder of Rimidi. "Their experience and expertise in optimizing care processes is integral to our mission as we strive to drive efficiency and effectiveness in managing chronic diseases using innovative technology."

Through the partnership, the Rimidi platform will synergize NAFLD-specific workflows with those of other cardiometabolic comorbidities, creating a population health-focused approach to optimizing care for patients with multiple complex chronic diseases.

The Kinetix Group and Rimidi are bringing the solution to market through their combined clinical workflow consulting expertise and technology expertise, with the goal of transforming care for patients with liver disease.

For more information, please contact Kristen Shea at 

The Kinetix Group is empowers life science companies to effectively engage with health system and payer customers by developing strategies and real world solutions aimed at impacting the right patient, at the right time, with the right care. TKG also works directly with health systems and payers to build and implement value-based delivery models for identified patient populations. To learn more, go to

NASHNET is a global Centers of Excellence Network represented by leading healthcare systems committed to NASH care delivery innovation. As a convener of NASH experts, NASHNET promotes collaboration and best practice sharing to develop standardized models of care, improve NASH care coordination, create population health strategies for fatty liver disease, and promote real world evidence research activities. To learn more, go to

Rimidi empowers clients to deliver more efficient healthcare, improve patient quality of life, and decrease the financial burden to patients and payers. Rimidi's platforms empowers patients and providers to identify gaps in chronic care management as well as the necessary steps to close those gaps, meet patient targets and create a more efficient cycle of care. To learn more, go to


2 Le, M.H., et al., Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States. PLoS One, 2017. 12(3): p. e0173499.

Editor Details

Last Updated: 31-Aug-2018